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Abstract
Background: Clear cell renal cell carcinoma (ccRCC), the most aggressive renal cancer, is characterized by early
lymph node metastases and bad prognosis. Most therapies targeting advanced or metastatic ccRCC are based, as
first-line treatment, on the administration of the vascular endothelial growth factor (VEGF) neutralizing antibody
termed Bevacizumab. Despite proven benefits, the expected results were not obtained for the majority of patients.
The possibility that an intricate interplay between angiogenesis and immune-checkpoints might exist lead us to
evaluate tumor angiogenesis, by means of VEGF expression together with the immune checkpoint HLA-G/ILT4.
Methods: Tumor specimens were obtained from patients from two separate cohorts: One from “Evita Pueblo”
Hospital from Berazategui, (Buenos Aires, Argentina) and the second includes patients surgically operated at the
Urology Department of Saint-Louis Hospital (Paris, France) with a confirmed ccRCC diagnosis.
Immunohistochemistry was performed with specific antibodies directed against HLA-G, VEGF-A, VEGF-C, D240,
CD34, ILT4 and Ca-IX. In addition, gene expression levels were measured in a cell line derived from a ccRCC patient
by semi-quantitative RT-PCR.
Results: Our results show that the highly vascularized tumors of ccRCC patients express high levels of VEGF and
the immune-checkpoint HLA-G. In addition, ILT4, one of the HLA-G receptors, was detected on macrophages
surrounding tumor cells, suggesting the generation of an immune-tolerant microenvironment that might favor
tumorigenesis. Notably, RT-qPCR analysis provided the first evidence on the transcriptional relationship between
HLA-G/ILT4 and the VEGF family. Namely, in the presence of HLA-G or ILT4, the levels of VEGF-A are diminished
whereas those of VEGF-C are increased.
Conclusions: In an effort to find new therapeutic molecules and fight against metastasis dissemination associated
with the poor survival rates of ccRCC patients, these findings provide the rationale for co-targeting angiogenesis
and the immune checkpoint HLA-G.
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Background
Clear cell renal cell carcinoma (ccRCC) is the most com-
mon epithelial tumor of the kidney that occurs in adults. It
is characterized by malignant epithelial cells with clear cyto-
plasm and a compact-alveolar or acinar growth pattern in-
terspersed with intricate, arborizing vasculature. ccRCC
accounts for approximately 70–80% of renal cancers. Prog-
nosis is generally poor due to insufficient early warning
signs and the difficulty to accurately predict tumor aggres-
siveness [1]. The WHO/ISUP 2016 grading system, which
replaces the Fuhrman grading system, is now the more ac-
curate system to classify tumor aggressiveness [2, 3].
The standard care for localized ccRCC remains surgi-
cal excision. Patients cannot be treated by radiation nor
chemotherapy. Metastases, at diagnosis, were observed
for 25–30% of the patients and less than 10% of these
patients survive more than five years [4–6]. Recurrence
occurs in 20–30% of the patients even after complete
nephrectomy of primary tumors.
A major breakthrough in the treatment of advanced or
metastatic ccRCC was the introduction, as first-line treat-
ment, of anti-angiogenesis therapies such as the adminis-
tration of the VEGF-A neutralizing antibody termed
Bevacizumab [7, 8]. VEGF-A, the most active isoform pro-
motes the induction of new blood vessels, vascular perme-
ability and cell migration and ultimately may lead to the
development of metastases [9–11]. Solid tumors charac-
terized by poorly organized abnormal vessels with altered
permeability cannot grow beyond 1–2mm in diameter
without neovascularization [9, 12], demonstrating that
tumor growth is dependent on angiogenesis. The degree
of intra-tumor angiogenesis in ccRCC might be quantified
by measuring the microvessel density (MVD) by means of
CD34 expression assessment. CD34 is predominantly
regarded as a marker of hematopoietic stem/ progenitor
cells. However, CD34 is now established as a marker of
several other non-hematopoietic cell types, including vas-
cular endothelium present within newly forming vessels
or those just trapped within tumor tissues [5, 13]. Yet, the
capacity of the MVD to predict disease recurrence and
survival remains controversial.
In recent years, the focus of ccRCC treatment was
shifted to therapies targeting the tumor and the im-
mune system simultaneously. Immune-therapies have
brought significant improvements in the outcome of
some cancer, providing unprecedented clinical bene-
fits [14]. In particular, immune checkpoint (IC) block-
ade cooperates with other anti-cancer therapies, to
increase the effectiveness of therapeutic protocols
[15]. IC are crucial for the maintenance of self-
tolerance and for the modulation of immune re-
sponses in order to minimize tissue damage. They re-
sult from the interaction between inhibitory ligand
molecules and their receptors present on immune
cells. Tumor cells can upregulate checkpoints and es-
cape destruction by the immune system [16, 17].
Recent findings indicated that in the tumor micro-
environment, an interconnection between VEGF signal-
ing and immunosuppression might exist, suggesting that
the combination of anti-VEGF agents and immune
checkpoint blockade might have enhanced synergistic
antitumor activity [18].
A recent described checkpoint is the non-classical class I
molecule human leukocyte antigen G (HLA-G) [19]. HLA-G
was first described to play a major role in foeto-maternal tol-
erance and tissue transplantation [20]. At present, the check-
point HLA-G has been found in most tumors analyzed. In
particular, high incidence of HLA-G expression has been re-
ported in ccRCC [21–23]. The role of HLA-G as a check-
point allowing tumor escape has been demonstrated in
murine models [24]. HLA-G has a broader inhibitory effect
than any other checkpoint since it can block all steps of anti-
tumor responses by acting on natural killer (NK) cells, B
lymphocytes, T lymphocytes and antigen-presenting cells
(APC) through direct interaction with its receptors [19].
Immunoglobulin-like transcript (ILT) 4, one of the HLA-G
receptors, was found in ccRCC [22] and non-small cell lung
cancer in which promotes tumor progression and metastases
by increasing the levels of VEGF-C [25], the best character-
ized and more efficient growth factor involved in lymphan-
giogenesis and lymphatic metastases [26–28].
In this context, the aim of this study is to explore the rela-
tionship between the immune checkpoint HLA-G/ILT4 and
tumor angiogenesis based on the expression of VEGF-A and
VEGF-C. The rationale is to determine whether combining
conventional anti-VEGF therapies with immunotherapies
might improve the outcome of patients with ccRCC.
Methods
Patients and tumors
Tumor specimens were obtained from patients from two
separate cohorts: One included fifty patients surgically op-
erated from 2006 to 2009 at the Urology Department of
“Evita Pueblo” Hospital from Berazategui, (Buenos Aires,
Argentina) with confirmed diagnostic of ccRCC, twenty
representative of these were presented in this study (Table
1). The second cohort includes patients surgically operated
in the Urology Department of Saint-Louis Hospital (Paris,
France) and largely described [22, 23]. Both groups of pa-
tients underwent radical nephrectomy for ccRCC as first
therapy. These renal tumors were classified as ccRCC by
experienced uropathologists according to the World Health
Organization (WHO) classification of tumors of the kidney
[29]. All patients that participated in this study gave their
free and informed writing consent. The study was approved
by the Institucional Hospital Evita Pueblo committee, the
COBIMED (Comité de Bioética y Ética de la Investigación
de la Facultad de Ciencias Médicas de la Universidad
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Nacional de La Plata) and the institutional review board of
Saint-Louis Hospital, Paris.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 4-μm-
thick, formalin-fixed, paraffin-embedded tumor tissue sec-
tions. The HLA-G labeling was performed with the murine
antibody 4H84, an IgG1 recognizing the alpha1 domain of
HLA-G isoforms (dilution 1:500, Santa Cruz Biotechnology,
Santa Cruz, CA) as described [23]. Its inhibitor receptor
ILT4 (dilution 1:50, polyclonal goat antibody, R&D sys-
tems) was concomitantly studied. The other primary anti-
bodies used are: anti-VEGF-A (dilution 1:50, clone C-1,
mouse monoclonal, Santa Cruz Biotechnology), anti-CD34
(dilution 1:1000, clone BI-3C5, mouse monoclonal, Santa
Cruz Biotechnology), anti-VEGF-C (dilution 1:50, rabbit
polyclonal, Abcam Inc), the lymphangiogenic growth factor
that plays an important role in tumor lymphangiogenesis,
anti-D2–40 (dilution 1:20, Mouse monoclonal, Abcam Inc),
a specific antibody for lymphatic vessel density (LVD)
which reacts with an O-linked sialoglycoproteins found on
lymphatic endothelium and anti-carbonic anhydrase
(CA)-IX (dilution 1:500, rabbit polyclonal, Novus Biologi-
cals), an enzyme over-expressed in VHL mutated tumors
and hypoxic tissues. Detection was performed using
DAKO EnVision+ System-HRP (DAKO Corporation,
Hamburg, Germany) for 30min and the reaction was de-
veloped using diaminobenzidine, and counter staining
with Mayer hematoxylin. Positive and negative controls
gave appropriate results for each procedure.
Microvessel density (MVD) quantification
MVD was assessed following CD-34 labeling using the cri-
teria of Weidner et al. [30]. A brown CD-34 stained endo-
thelial cell or groups of endothelial cells that clearly
separate from adjacent microvessels, tumor cells or other
connective tissue elements, were considered as a single
countable microvessel. The vessels > 50 μm wide were not
considered as neoangiogenesis. Three fields of the most
intense vascularization (hotspots) were analyzed for each
tumor. The data allow us to obtain the MVD index for
each tumor.
Cell lines
The RCC7 cell line used in this study derives from a pa-
tient with ccRCC [31] and was kindly provided by Anne
Caignard. The cell line is routinely tested for mycoplasma
contamination by using the LookOut®Mycoplasma PCR
Table 1 Clinical and pathological characteristics of the ccRCC patients from the Berazategui Hospital, Argentina. Reference values for
Who/ISUP grade, age ranges, MVD index, metastasis, overall survival, local infiltration, tumor size (pT), expression of VEGF-A, HLA-G
and ILT4, are provided. The expression levels of markers revealed by IHC were noted as follows: + weak staining; ++ moderate
staining; +++ strong staining. Survival, reported as overall survival, is expressed in years considered at 1, 3 or 5 years post-surgery;
MVD: Microvessel density index (central and peripheral zone); detection of metastasis: Yes (Y) or Not (N)
Patient Who/ISUP Age Range Metastasis Survival VEGF-A MVD HLA-G ILT4 Local infiltration pT
1 1 70–79 N < 5 + 36 ++ +++ No T1
2 2 50–59 N > 5 + 29 ++ +++ Capsule T2
3 2 60–69 Y < 3 + 14 ++ +++ Renal vein T3
4 2 50–59 N > 5 ++ 24 +++ ++ Capsule T1
5 2 50–59 N > 5 + 38 +++ ++ No T1
6 2 60–69 N > 5 ++ 54 +++ +++ Capsule T1
7 2 60–69 N > 5 +++ 16 ++ +++ Capsule T1
8 2 50–59 N > 5 ++ 33 +++ +++ Capsule T2
9 2 50–59 N > 5 + 35 +++ +++ Capsule T1
10 2 50–59 N > 5 ++ 34 ++ +++ No T1
11 2 50–59 N > 5 + 33 ++ + Capsule T1
12 2 40–49 N > 5 + 42 ++ + No T1
13 2 50–59 N < 5 ++ 31 +++ +++ Perirenal tissues T3
14 3 70–79 N > 5 +++ 20 +++ +++ Renal vein T3
15 3 70–79 Y > 5 ++ 16 ++ +++ Renal vein T3
16 3 50–59 N > 5 + 19 ++ +++ Perirenal tissues T3
17 3 50–59 N < 3 ++ 27 ++ +++ Perirenal tissues T3
18 3 70–79 N > 5 ++ 26 ++ +++ No T1
19 3 50–59 N > 5 + 28 ++ + No T1
20 4 60–69 Y < 1 ++ 26 + +++ Renal vein T3
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detection kit. These cells express VEGF-A and VEGF-C
but not HLA-G nor ILT4. RCC7 cells expressing HLA-G
and ILT4 were obtained after lentiviral transduction of
their respective cDNA in plasmid pWPXL (Addgene plas-
mid # 12257). The M8 HLA class I-positive melanoma cell
line expressing HLA-G was previously described [32].
Production of lentiviral particles containing HLA-G or ILT4
cDNAs
HLA-G1 cDNA was introduced into the plasmid pWPXL
(10,510 bp), between the BamH1 and NdeI sites, just 3 ‘of
the EF-1α promoter. This was followed by a “red” variant
of the GFP (Aequorea victoria green fluorescent protein
jellyfish), named Neptune that has been brought under
control of the CMV promoter. The ILT4 cDNA (1797 bp)
was introduced into the plasmid pWPXL between the
Ml1 and NdeI sites, just 3 ‘of the EF-1α promoter. These 2
plasmids were used to produce lentivirus WPXL ΔU3
SIN, envelope VSV-G, OGM group II, class 2 at 1.20E +
08 TU and 1.00E + 08 (Transduction Unit) / ml respect-
ively at the Plateforme Vecteurs Viraux et Transfert de
Gènes (VVTG), SFR Necker, US 24, UMS 3633, Paris.
Lentivirus (107 pfu/ml) expressing either HLA-G or ILT4
were added to RCC7 cells (10.000 cells/well in 12-well
plates) at a multiplicity of infection (MOI) of 5. Cells were
incubated overnight at 37 °C in a humidified incubator
(5% CO2). Media containing lentiviral particles were then re-
moved from wells. Cells were washed and cultured in fresh
medium (DMEM +10% FBS). To expand the culture, cells
arrived at 90% of confluence were plated in a T-25 cm2 flask.
The efficiency of transduction (approximately 30%) was de-
termined using fluorescence microscopy and flow cytome-
try. Transduced cells were then sorted using BD FACSAria
III (BD Biosciences-US) to obtain 95% of purity.
RNA extraction
Total RNA was isolated from tissue sections manually
crushed in Trizol™ Reagent (LifeTechnologie, ref. 15,596,
026). After chloroform separation, the RNA was purified
using miRNeasy mini Kit (Qiagen, ref. 217,004) accord-
ing to the manufacturer’s instruction, with a DNase
extra step treatment (Qiagen, ref. 79,254). The concen-
tration and purity of RNAs was assessed using a Nano-
drop spectrophotometer.
Real time RT-PCR
Total RNA was used as template for cDNA production using
High Capacity cDNA Reverse Transcription kit (Applied
Biosystems, USA). For cDNA amplification Power SYBR
Green PCR Master Mix (Applied Biosystems, USA) was
added and the mixture was poured up into a MicroAmp Op-
tical 96-well Reaction Plate (Applied Biosystems, USA) that










Actin B: 5′-TCCTGTGGCATCCACGAAACT; 5′-
GAAGCATTTGCGGTGGACGAT.
Thermal cycling was performed using ABI-7000
(Applied Biosystems, USA) according to manufacturer’s
instruction with an initial denaturation at 95 °C for
10 min, 40 cycles at 95 °C for 15 s, and 60 °C for 1
min. Values of cycle threshold (Ct) were used for cal-
culations of fold changes in mRNA abundance using
2-ΔΔCt method.
Statistical analysis
The expression levels were analyzed by ANOVA,
followed by Kramer Multiple Comparisons Test (using
95–99% confidence interval).
Results
Clinicopathologic characteristics of patients with ccRCC
A retrospective study was performed on twenty repre-
sentative patients (Table 1) from a total of fifty included
in the Argentinian cohort, after obtaining ethical com-
mittee clearance.
The tumors derived from fifteen men and five women,
of which 11 patients were 50–60 years old. This propor-
tion is consistent with what is expected for ccRCC pa-
tients since this neoplasm is highly aggressive and affects
relative young people [5]. The WHO/ISUP grade of the
20 patients are as follows: Grade 1:1; Grade 2:12; Grade
3: 6 and Grade 4:1, being grade 1 the least aggressive
type and grade 4 the most aggressive. Their clinical his-
tory revealed that six patients did not survive 5 years
post-surgery, of whom three developed metastases
(Table 1). The reason of patients’ death within 5 years
was due to: cardiac decompensation (patients 1 and 17),
pulmonary and cerebral metastases (patient 20), breast
cancer (patient 14) and tumor progression (patients 3
and 15). Local infiltration data and tumor size status
(pT) are also shown (Table 1). The correlation analysis
revealed that when the WHO/ISUP grade is high, usu-
ally the pT status is high. For WHO/ISUP group 1 there
is one patient with pT1. For WHO/ISUP group 2, 67%
of patients are pT1, 17% are pT2 and 17% are pT3. For
WHO/ISUP group 3, 67% of patients are pT3 and 33%
are pT1. For WHO/ISUP group 4 there is one patient
with pT3 (Table 2), being pT1 the smallest tumor size
and pT4 the largest.
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Immuno-histochemical evaluation of tumor angiogenesis
in ccRCC
To evaluate angiogenesis, we first carried out IHC on
the twenty ccRCC samples using specific antibodies for
VEGF and CD34. The results show that all tumors sam-
ples expressed VEGF-A in at least one area of the tumor.
For comparative purpose with the subsequent genes ana-
lyzed in this study, the expression was scored according
to stain intensity: weak, moderate or high (Table 1). Of
note, high levels of VEGF-A do not correlate with the
highest WHO/ISUP grade.
To test whether the angiogenic capacity of a tumor in-
creases parallel to its microvasculature, antibodies di-
rected against the CD34 antigen were used to calculate
the MVD index. A brown CD-34 stained endothelial cell
or groups of endothelial cells that clearly separate from
adjacent microvessels, tumor cells or other connective
tissue elements, were considered as a single countable
microvessel. According to the results, tumor samples
were divided into two groups: group 1, with more than
20 microvessels per field and group 2, with less than 20
microvessels per field. The MVD tumor mean was 29.05
microvessels/ field. Only four patients belong to the sec-
ond group confirming that ccRCC samples have import-
ant tumor neoangiogenesis. Notably, in most patients
with MVD > 20, VEGF-A levels are low (+ or ++) and
those with MVD < 20, VEGF-A are high (Fig. 1a). This is
no longer the case for patients that have developed me-
tastases for whom levels of both, CD34 and VEGF-A,
were low. We observed high MVD index in the periph-
eral tumor area compared with the central region, but
all tumor regions have significantly higher MVD index
compared with normal adjacent renal tissue (Fig. 1b). It
is likely that studying the difference between the intra-
and peritumoral MVD might lead in the future to a bet-
ter assessment of prognosis.
Immuno-histochemical survey of the immune checkpoint
HLA-G/ILT4
Since a possible interplay between angiogenesis and
immune-checkpoints has lately been evoked as a novel
strategy to improve the success of cancer treatments, we
ought to evaluate the potential co-expression of VEGF-
A with the immune checkpoint HLA-G/ILT4.
First, tumor samples were analyzed by IHC with anti-
body 4H84, which recognizes the alpha1 domain of
the seven reported HLA-G isoforms. IHC staining was
detected in at least one area of all samples. This expres-
sion was variable among patients and the different areas
of the samples in accordance with previous studies [23].
The staining was membranous and cytoplasmic and was
annotated according to the stain intensity: weak, moder-
ate or high (Table 1).
Next, we assessed the expression of ILT4, the HLA-G
receptor. All tumor samples from the twenty Argentin-
ian patients were positively labeled (Table 1). The stain
was detected on some stromal macrophages, plasma
cells and infiltrating lymphocytes. Fig. 2 shows two rep-
resentative examples. Together, the high expression of
HLA-G and its receptor ILT4 is consistent with the gen-
eration of an immune-tolerant microenvironment as
previously described [17, 33].
Marked expression heterogeneity of ccRCC specimens
The retrospective study clearly demonstrates high ex-
pression of VEGF-A, HLA-G and ILT4, but does not
inform us whether these molecules are co-expressed
in the same areas of the tumor. Therefore, we have
performed an IHC study. Due to the potential
Table 2 Correlation analysis between WHO/ISUP grade and
tumor size status (pT). The table shows relative frequencies
obtained from the data of Argentinian patients
WHO/ISUP T1 T2 T3 Total
1 1,00 0,00 0,00 1,00
2 0,67 0,17 0,17 1,00
3 0,33 0,00 0,67 1,00
4 0,00 0,00 1,00 1,00
Total 0,55 0,10 0,35 1,00
Fig. 1 Measure of MVD index. a Correlation between MVD index and VEGF-A expression. b MVD Average index in tumor and adjacent non-tumor
regions. Normal: adjacent non-tumor tissue; central: tumor central zone; peripheral: tumor peripheral zone. The standard deviation is shown
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heterogeneity of expression, tumors obtained from pa-
tients from the French Saint Louis Hospital cohort
[22] were cut in several pieces (3 to 6 according to
the tumor size). Since these tumors were previously
asses for the expression of HLA-G (23), we purposely
chose HLA-G-positive and HLA-G-negative tumors in
order to evaluate whether correlations might exist
with the other markers (VEGF-A, CD34, VEGF-C,
D2–40, ILT4 and CA IX).
The IHC results reveal positive staining for the four
markers VEGF-A, CD34, HLA-G and ILT4 which
confirms the retrospective results. Consistent with our
previous studies [23], HLA-G and ILT4, were not de-
tected on normal parenchyma. Some tumor regions
exhibited strong immunostaining with anti-VEGF-A
whereas no label was found for HLA-G or ILT4
(Fig. 3). Similarly, some tumor regions exhibited
strong immunostaining with anti-HLA-G or anti-ILT4
whereas no label was found for VEGF-A. In addition,
the IHC staining revealed that regions showing strong
labeling for D2–40 were also highly stained with anti-
bodies directed against HLA-G and ILT4. Moreover,
no concordance was found between these expression
profiles and those of VEGF-C. The immunostaining
with anti-carbonic anhydrase (CA)-IX was strongly
observed in all tumor samples, which would correlate
with a pseudo-hypoxic tumor status that is commonly
present in this neoplasia and is associated with the
VHL mutation, consistent with previous literature
reports [34, 35].
Altogether, the IHC study reveals significant posi-
tive labeling of angiogenic and immune-checkpoints
markers in ccRCC samples. However a clear hetero-
geneity was observed with no perceptible association
among markers. Given this heterogeneity and the var-
iety of factors that can regulate their expression, a
more detailed molecular analysis appears to be neces-
sary to better understand the basis of ccRCC.
The immune-checkpoint HLA-G/ILT4 is involved in the
expression of VEGF-A and VEGF-C
In view of the heterogeneity of the IHC results, we aimed
to analyze more specifically the influence of HLA-G and
ILT4 on the expression of VEGF genes at the molecular
level. To overcome the difficulty that represents analyzing
transcriptional regulation of genes in a heterogeneous
tumor microenvironment, the analysis was performed in
the cell line RCC7, which constitutes a valuable cellular
model for ccRCC [31].
The expression levels of HLA-G, ILT4, VEGF-A and
VEGF-C were analyzed by RT-PCR with specific primers.
The results showed that VEGF-A and VEGF-C are highly
expressed in the RCC7 cell line whereas the immune
checkpoint HLA-G/ILT4 is not. We therefore transduced
RCC7 cells with lentivirus carrying the cDNA of HLA-G
or ILT4 respectively. The expression of HLA-G and ILT4
in these transduced cells was first confirmed by RT-PCR
(Fig. 4a and 4b). Then, to determine whether the presence
of HLA-G or ILT4 could modulate the expression of the
VEGF genes, we measured VEGF-A and VEGF-C
Fig. 2 Representative IHC staining of ILT4 in tumor tissues of two patients with ccRCC (H&E and immunoperoxidase stains are also shown). No
label was detected in normal adjacent tissues
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mRNA levels in the three cell lines (RCC7, RCC7-
HLA-G1 and RCC7-ILT4). The results show a 70%
decrease in the levels of VEGF-A in the presence of
HLA-G and a 60% decrease in the RCC7 cells
expressing ILT4. In sharp contrast, the levels of
VEGF-C were 2,5-fold higher in the RCC7 cells ex-
pressing HLA-G and ILT4 than those of controls
(Fig. 4c and 4d).
Fig. 3 Immunohistochemical labeling for CA-IX, VEGF-A VEGF-C, CD34, D2–40, HLA-G and ILT4 in distinct tumor regions of two representative
clear cell renal-cell carcinoma samples. Expression is observed as a dark brown color. (H&E and immunoperoxidase stains are also shown)
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Altogether, a significant increase in the levels of
VEGF-C (p < 0,01) was observed in cells expressing
HLA-G or ILT-4 whereas the VEGF-A expression levels
were weaker (p < 0,01) in cells expressing HLA-G or
ILT-4 than in wild-type RCC7.
To determine whether the effect of HLA-G was cell-
dependent, we measure the expression of VEGF-C in the
melanoma cell line M8 expressing HLA-G [32]. The re-
sults demonstrate that VEGF-C is induced also in M8
cells (Fig. 4e and f), proving the direct role of HLA-G on
VEGF-C expression.
Discussion
The standard care for advanced or metastatic ccRCC pa-
tients, when nephrectomy is not efficient enough, is to
use anti-angiogenic therapies aimed to hinder blood sup-
ply for the tumor, mainly by the administration of anti-
VEGF-A monoclonal antibody Bevacizumab [36]. Des-
pite proven benefits, these treatments have not given
fully expected results in the majority of patients [7, 37]
emphasizing the need to design more effective protocols
to control ccRCC proliferation and increase survival of
patients. Within this context, we evaluated the relation-
ship between angiogenesis and immune checkpoints.
To evaluate angiogenesis in patients with ccRCC, we
sought to determine first whether a correlation exists be-
tween the tumor’s grade, VEGF-A positivity and MVD
calculated by the CD34 labeling. We observed that all
the tumors analyzed were positive for VEGF-A expres-
sion in at least one area of the tumor and have an
Fig. 4 Effect of the checkpoint HLA-G/ILT4 on the expression of VEGF genes. RNA prepared from RCC7-wild type (wt), RCC7-HLA-G1, RCC7-ILT4, M8- wild
type (wt) and M8-HLA-G1 cell lines were subjected to semi-quantitative RT-PCR using specific primers. The symbol (***) shows that differential expression is
statistically significant (p< 0,01). a HLA-G1 expression in the three cell lines; b ILT4 expression in the three cell lines; c VEGF-A expression in the three cell
lines; d VEGF-C expression in the three cell lines ; e HLA-G expression in M8 (wt) and M8-HLA-G1 and f VEGF-C expression in M8-(wt) and M8-HLA-G1.
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important MVD. Nevertheless, tumor’s grade was found
to be independent of both markers. In addition, we
found a negative correlation between VEGF-A and the
MVD index. When VEGF-A expression was high, the
MVD index was low (less than 20 microvessels per field),
whereas when the VEGF-A expression was low, the
MDV index was high. This unexpected situation might
be explained by the fact that a well-irrigated tumor re-
gion (ie MVD high) does not need the formation of new
vascular vessels, consequently VEGF-A expression by
tumor cells decreases. Conversely, when the tumor re-
gion is poorly irrigated (ie MVD low), this low oxygen
(hypoxic) microenvironment will induce the expression
of the hypoxia-inducible factor (HIF) by tumor cells,
which directly stimulates the expression of VEGF-A
[38]. This is no longer the case for patients that have de-
veloped metastasis whose levels of both, MVD and
VEGF-A, are low. In addition, a higher MVD was found
in the peripheral zone compared with the central region.
It is likely that the peripheral tumor zone have the most
metabolically active tumor cells, which are continuously
expanding. Such a process would require good oxygen-
ation provided by intense neo-angiogenesis. In addition,
we observed high levels of CA-IX that might correspond
with pseudo-hypoxic areas as previously reported in lit-
erature (34, 35). It still remains unclear whether normal
vessels and tumor vessels show the same immune-
reactivity with various antibodies [39].
In the search of complementary angiogenic strategies
to improve the clinical response of ccRCC patients, we
have asked whether combining conventional anti-
angiogenic therapies with blockade of the immune
checkpoint HLA-G/ILT4 might be associated with a sig-
nificant improvement in durable response rate since pre-
vious studies suggested an intricate interplay between
angiogenesis and immune-surveillance [38]. To this end,
we have simultaneously analyzed the expression of
VEGF genes with the immune-checkpoint HLA-G/ILT4.
The transcriptional analysis provided the first evidence
on the relationship between the HLA-G/ILT4 and the
VEGF family. We demonstrated in the ccRCC7 cell line
engineered to overexpress HLA-G or ILT4, that in the
presence of one of these two molecules, the levels of
VEGF-A are reduced whereas those of VEGF-C increase.
This is consistent with a previous report showing that in
a non-small cell lung cancer (NSCLC), ILT4 plays an
important role in promoting tumor growth and metasta-
ses by the upregulation of VEGF-C expression [22, 40–
42] which in turn induces the abnormal growth of
peripheral lymphatic vessels and increases their perme-
ability facilitating lymphatic metastasis. ILT4 and VEGF-
C were also shown to be involved in the epithelial-to-
mesenchymal-transition (EMT) process, which endows
transformed endothelial cells with the ability to invade
and disseminate [43, 44]. Moreover, the regulation of
VEGF-C by HLA-G was shown to be cell-independent
since the levels of VEGF-C also increase in a melanoma
cell line when transfected with HLA-G. As ILT4, HLA-
G was associated with tumor metastases and poor sur-
vival in an animal model of ovarian cancer [45].
Altogether, our results further suggest that the presence
of the immune-checkpoint HLA-G/ILT4 bring forth an
effective signal transmission to form an immunosuppres-
sive microenvironment and enhance the formation of
new tumor lymphatic vessels increasing therefore the
metastatic capacity of tumor cells [28].
Conclusions
The data reported here may be valuable to control
tumor growth and improve outcomes for patients with
ccRCC. Even though the different regulatory cascades
which simultaneously involve either VEGF-A or VEGF-
C are still to be clearly determined, we propose consid-
ering the establishment of protocols associating the anti-
VEGF-A antibody Bevacizumab, which should prevent
the increase in the levels of VEGF-A, with the blockade
of HLA-G, which should prevent tumor progression and
metastases by decreasing the levels of VEGF-C and re-
activate the immune system. We believe that the design
of these combined therapies would be the new direction
to be attempted in the future to improve the effective-
ness of treatment strategies for patients with ccRCC.
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